Hanol Amine Plus Injection

Adult dosage

For peripheral venous administration, typically 200-400 mL is infused as a slow drip. The administration rate is based on approximately 120 minutes per 200 mL (around 25 drops per minute), aiming for a total amino acid amount of approximately 10 g to be utilized within 60 minutes. For central venous administration, generally 400-800 mL is continuously infused into the central vein using high-calorie infusion methods daily. Adjustments should be made according to age, symptoms, and body weight.

Children's dosage

For peripheral venous administration in children, it should be administered slowly.

This medication must be used strictly under the guidance of a physician. It should not be used in patients with hepatic coma or those at risk of hepatic coma. It should also not be administered to patients with severe renal dysfunction or elevated blood nitrogen levels. Patients with issues in nitrogen metabolism should not be given this medication. Patients with severe heart failure or pulmonary edema should also avoid this medication. It should not be administered to patients with very low or absent urine output. If sodium and chloride ions are included, it should not be given to patients with elevated sodium and chloride levels. Patients with a history of myocardial infarction or current myocardial infarction should also refrain from using this medication. Caution is warranted when administering to patients with severe acidosis or congestive heart failure. If sodium ions are included, caution should be exercised in patients with edema due to sodium retention. If potassium ions are contained in amounts above 5 mmol/L, the medication should be administered with caution to patients with hyperkalemia or potassium retention. Patients with liver or kidney impairments also require careful monitoring. Sodium bisulfite included in this medication may cause allergic reactions, particularly in asthma patients, where symptoms can occur more frequently. If hypersensitivity reactions such as rashes occur during the use of this medication, administration should be immediately stopped. Occasionally, gastrointestinal symptoms such as nausea or vomiting may occur. Cardiac-related symptoms may include chest discomfort, palpitations, rapid pulse, and elevated blood pressure. Rapid administration in large volumes may cause acidosis, hence caution is advised. Serious side effects may include chills, fever, headache, dyspnea, and shock. Metabolic complications can include acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, etc. Patients with reduced liver or kidney function may experience elevated blood BUN levels. Patients with liver failure are at risk for serum amino acid imbalance, metabolic alkalosis, and coma, necessitating caution. During large-volume administration, electrolyte balance must be carefully monitored, especially when used with electrolyte-containing solutions. In cases of overdose, metabolic alkalosis can occur due to the acetate ions present, and care should be taken. Careful administration is required to prevent fluid overload in patients with a history of kidney disease, lung disease, or heart disease. Diabetes patients should frequently monitor blood sugar levels during administration. When used concurrently with tetracycline antibiotics, the protein-sparing effect may decrease, so caution is advised during co-administration. Safety has not been established in pregnant women, so it should only be used when the therapeutic benefit outweighs the risks. In children, concentrations should be kept low due to immature liver function, and blood ammonia levels should be regularly monitored. Elderly patients require careful dosage adjustments due to decreased bodily functions, and slow administration rates should be followed. This medication contains electrolytes, so caution regarding electrolyte balance is necessary during large volumes of administration, and intravenous administration should be slow. Rapid infusion may cause chills or vomiting and may increase amino acid loss through the kidneys. At lower temperatures, it is advisable to warm it to body temperature for use. Preparation and management of the solution should be done in a sterile manner, and special attention should be paid to the sterilization of injection equipment. Before administration, ensure the solution is transparent and do not use if it is discolored or leaked. During storage, it should be kept sealed from air and moisture, and the remaining solution should be used within 24 hours after opening. If crystals form, dissolve them at 50-60 degrees and allow it to cool to body temperature before use. Soft bag products do not require venting, while vial products should be vented just prior to use. If discoloration or leakage is present in the liquid, or if there are droplets on the exterior, do not use; also do not use if the rubber stopper protective film is peeled off. Use should be accurate based on the graduation of the container.

Serious side effects

Allergic reactions such as sulfite anaphylaxis, asthma attacks, dyspnea, respiratory arrest, shock, bronchospasm, liver failure, kidney failure, coma

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid pulse (tachycardia)
• elevated blood pressure
• chills
• fever
• headache

This medication should be stored in a sealed container to prevent air or moisture ingress. It is advisable to keep it away from direct sunlight, at normal room temperature, neither too hot nor too cold.

Appearance

A colorless to pale yellow transparent liquid contained in a polypropylene aqueous injection vial.

Package unit

200 mL/bag, 250 mL/bag